Íò²©Ë®¾§¹¬

ZHU Qiaoli ^¢Ù

(Zhoukou Maternal and Child Health Hospital / Zhoukou Children¡äs Hospital, Zhoukou 466000, China)

Abstract Objective: To investigate the clinical efficacy of montelukast sodium combined with budesonide in the treatment of children with cough variant asthma (CVA). Methods: A total of 150 children with CVA were selected into the study group and control by the table of random number group, each with 75 cases. The control group revived treatment with budesonide, while the study group were treated with montelukast sodium on the basis of the treatment for the control group. The clinical efficacy, pulmonary function, the level of serum inflammatory factors and immune function were compared between both groups. Results: The total effective rate was 97.33 % in the study group, which was higher than 88.00 % in the control group, the difference was statistically significant (P<0.05); compared with the control group, the study group had much higher FVC, FEV 1 , PEF, IFN-¦Ã, IgA, IgM levels and lower IL-4, TNF-¦Á and IgE levels after one month of treatment (P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Montelukast sodium combined with budesonide is effective in the treatment of children with CVA, which can significantly improve the control effect of inflammation, promote the improvement of lung function and immune function. Besides, it is of high safety.

Keywords: cough variant asthma; montelukast sodium; budesonide

DOI:10.19296/ j.cnki.1008-2409.2023-01-012

PDF download:click to download